Stock Scorecard

Stock Summary for Regulus Therapeutics Inc (RGLS) - $8.08 as of 6/13/2025 3:51:36 PM EST

Total Score

9 out of 30

Safety Score

32 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RGLS

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RGLS

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RGLS

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RGLS

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RGLS (32 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for RGLS

Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space 6/9/2025 12:44:00 PM
Buy These 5 Low-Leverage Stocks Amid Volatile Market Sentiment 5/30/2025 2:15:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - Kronos Bio ( NASDAQ:KRON ) , Regulus Therapeutics ( NASDAQ:RGLS ) 5/15/2025 10:52:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. ( Nasdaq - KRON ) , Regulus Therapeutics Inc. ( Nasdaq - RGLS ) , Longevity Health Holdings, Inc. ( Nasdaq - XAGE ) , Southern States Bancshares, Inc. ( Nasdaq - SSBK ) 5/15/2025 8:17:00 PM
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Glaukos ( NYSE:GKOS ) , Parsons ( NYSE:PSN ) 5/1/2025 5:40:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. ( Nasdaq - KRON ) , Regulus Therapeutics Inc. ( Nasdaq - RGLS ) , Coeptis Therapeutics Holdings, Inc. ( Nasdaq - COEP ) , Pacific Premier Bancorp, Inc. ( Nasdaq - PPBI ) 5/1/2025 3:27:00 PM
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - INVO Fertility ( NASDAQ:IVF ) , Jeffs Brands ( NASDAQ:JFBR ) 4/30/2025 4:24:00 PM
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Novartis ( NYSE:NVS ) 4/30/2025 3:22:00 PM
S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results - E-Home Household Service ( NASDAQ:EJH ) , Caterpillar ( NYSE:CAT ) 4/30/2025 1:52:00 PM
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure 4/30/2025 11:10:00 AM

Financial Details for RGLS

Company Overview
Ticker RGLS
Company Name Regulus Therapeutics Inc
Country USA
Description Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 8.08
Price 4 Years Ago 3.15
Last Day Price Updated 6/13/2025 3:51:36 PM EST
Last Day Volume 970,987
Average Daily Volume 1,339,735
52-Week High 8.35
52-Week Low 0.83
Last Price to 52 Week Low 873.49%

Valuation Measures
Trailing PE N/A
Industry PE 22.59
Sector PE 40.97
5-Year Average PE -3.19
Free Cash Flow Ratio 11.38
Industry Free Cash Flow Ratio 17.94
Sector Free Cash Flow Ratio 31.90
Current Ratio Most Recent Quarter 16.31
Total Cash Per Share 0.71
Book Value Per Share Most Recent Quarter 1.04
Price to Book Ratio 8.13
Industry Price to Book Ratio 34.46
Sector Price to Book Ratio 30.10
Price to Sales Ratio Twelve Trailing Months 7.43
Industry Price to Sales Ratio Twelve Trailing Months 120.34
Sector Price to Sales Ratio Twelve Trailing Months 34.15
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 69,234,000
Market Capitalization 559,410,720
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -54.34%
Reported EPS 12 Trailing Months -0.68
Reported EPS Past Year -0.15
Reported EPS Prior Year -0.87
Net Income Twelve Trailing Months -47,523,000
Net Income Past Year -46,358,000
Net Income Prior Year -30,037,000
Quarterly Revenue Growth YOY 27,678.00%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 49,460,000
Total Cash Past Year 38,528,000
Total Cash Prior Year 23,767,000
Net Cash Position Most Recent Quarter 46,666,000
Net Cash Position Past Year 33,855,000
Long Term Debt Past Year 4,673,000
Long Term Debt Prior Year 4,673,000
Total Debt Most Recent Quarter 2,794,000
Equity to Debt Ratio Past Year 0.94
Equity to Debt Ratio Most Recent Quarter 0.96
Total Stockholder Equity Past Year 76,408,000
Total Stockholder Equity Prior Year 21,187,000
Total Stockholder Equity Most Recent Quarter 69,028,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -43,923,000
Free Cash Flow Per Share Twelve Trailing Months -0.63
Free Cash Flow Past Year -42,013,000
Free Cash Flow Prior Year -27,381,000

Options
Put/Call Ratio 259.57
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.59
MACD Signal 0.74
20-Day Bollinger Lower Band -2.36
20-Day Bollinger Middle Band 3.80
20-Day Bollinger Upper Band 9.95
Beta 0.37
RSI 76.57
50-Day SMA 2.33
150-Day SMA 1.82
200-Day SMA 2.29

System
Modified 6/14/2025 9:03:22 AM EST